GRI Bio’s Financial Runway Extends to 2027 Amid Clinical Push
21.02.2026 - 06:29:04 | boerse-global.de
Following a successful restructuring of its balance sheet, GRI Bio is now channeling its resources into advancing the clinical programs for its pipeline targeting fibrotic and autoimmune conditions. A series of capital raises completed early in 2026 has strengthened the company’s liquidity, providing an operational funding window that stretches into the first quarter of 2027. The critical question for investors is whether management can leverage this extended timeframe to deliver pivotal clinical data.
The company’s core technology platform involves modulating natural killer T (NKT) cells. Its lead asset, GRI-0621, is in development for idiopathic pulmonary fibrosis (IPF). GRI Bio is currently evaluating biomarker data and lung function metrics from ongoing Read more...
